Business
Kintara Therapeutics to Present at the JMP Securities Life Sciences Conference
SAN DIEGO, June 10, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the
About this update from Tuhura Biosciences, Inc.
[{"type":"text","content":"SAN DIEGO, June 10, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) (\"Kintara\" or the \"Company\"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that President and CEO Robert E. Hoffman will present a corporate overview at the JMP Securities Life Sciences Conference. The conference is being held on June 15 – 16, 2022 at the Lotte New York Palace Hotel.\nPresentation Date:\n Thursday, June 16, 2022\nTime:\n 11:30am ET\nWebcast Link:\n https://wswcom/webcast/jmp54/ktra/1682208\nA live webcast of the presentation at the JMP Securities Life Sciences Conference will be available on https://ir.kintara.com/news-events. A replay of the webcast will be available for 30 days after the date of the presentation.\nMr. Hoffman will be available for one-on-one meetings with registered attendees of the conference.\nAbout KintaraLocated in San Diego, California, Kintara is dedicated to the development of novel cancer therapies for patients with unmet medical needs. Kintara is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for Glioblastoma Multiforme (GBM) and REM-001 for Cutaneous Metastatic Breast Cancer (CMBC).\nVAL-083 is a \"first-in-class,\" small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including central nervous system, ovarian and other solid tumors (e.g., NSCLC, bladder cancer, head and neck) in U.S. clinical trials sponsored by the National Cancer Institute (NCI). Based on Kintara's internal research programs and these prior NCI-sponsored clinical studies, Kintara is currently advancing VAL-083 in the GBM AGILE study to support the development and commercialization of VAL-083 in GBM.\nKintara is also advancing its proprietary, late-stage photodynamic therapy platform that holds promise as a localized cutaneous, or visceral, tumor treatment as well as in other potential indications. REM-001 therapy has been previously studied in four Phase 2/3 clinical trials in patients with CMBC who had previously received chemotherapy and/or failed radiation therapy. With clinical efficacy to date of 80% complete responses of CMBC evaluable lesions, and with an existing robust safety ...